作者: Flávia de Pereira , Aliny de Lima , Cesar Augusto Sam Tiago Vilanova-Costa , Wanessa Pires , Alessandra de Santana Braga Barbosa Ribeiro
关键词:
摘要: Chemotherapy is a common treatment for leukemia. Ruthenium complexes have shown potential utility in chemotherapy and photodynamic therapy. The identification of new chemotherapeutics agents critical further progress the generally lower toxicities compared to cisplatin attributed their specific accumulation cancer tissues. Based on these evidences, present work we studied cytotoxic activity ruthenium(III) compound cis-tetraammine(oxalato)ruthenium(III) dithionate - {cis-[Ru(C2O4)(NH3)4]2(S2O6)} against human chronic myelogenous leukemia cells (K-562) tumor cell line. tested induces death dose time dependent manner K-562 cells. It found that effect was improved linearly while prolonging incubation time. Compared cycle profiles untreated cells, flow cytometric analysis indicated sub-G1 arresting ruthenium In our study, shows significant increase tailed any concentrations with negative control. Consequently, concentration might be associated cytotoxicity direct DNA. Thus, it can deducted ruthenium-based compounds selectivity enter both normal Additional studies are needed determine molecular mechanisms active components evaluate vivo anticancer dithionate.